BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company announced its 3Q2024 financial results, which showed continued revenue growth that beat estimates and the third-consecutive profitable quarter.
